Switching from RxFul without disrupting refill day

Before moving prescriber volume, confirm the platform layer change does not disrupt the pharmacy layer underneath. First, check formulary coverage: list your highest-volume SKUs — semaglutide, tirzepatide, your hormone and peptide lines — and confirm the LegitScript-certified 503A partners assigned to your Fizy Health clinic can fill them. Because both RxFul and Fizy Health are infrastructure above compounders, not pharmacies themselves, coverage is the first thing to verify.

Second, review your RxFul agreement for notice period, minimum commitment, tier downgrade rules, and termination terms before you reduce volume — these are clinic-specific and belong in your own contract, not assumptions. Third, decide what carries over: patient demographics, common SIGs, and repeat-order SKUs. None of this requires an EMR migration. If you still need clinic-branded patient checkout, RxFul can remain live for that layer while Fizy Health handles prescriber batch ordering — they are complementary, not mutually exclusive.

The lowest-risk path is to run Fizy Health alongside RxFul for one or two refill cycles rather than cutting over cold. Create a free account at app.fizy.health, complete clinic and prescriber verification (NPI and DEA validated at onboarding), and add patients from your existing list or create them inline while building your first cart. Open catalog and cart for your top GLP-1 and hormone lines and compare pass-through per-vial cost against RxFul's all-in economics — drug cost plus any monthly SaaS tier you pay for catalog access.

Run your first validated batch cart for a single refill day: add today's patient lines on the prescriber side, let cart validation catch SIG and licensure issues before checkout, and submit one payment. Tracking and in-app support start per line from day one. Keep RxFul active for patient-facing flows until prescriber workflow proves out. If pass-through pricing plus zero monthly platform fee does not beat your RxFul all-in cost on top SKUs, staying is the right call — switch on the numbers, not the pitch.